淋病奈瑟球菌对头孢曲松耐药性及耐药机制研究进展

Ceftriaxone resistance in Neisseria gonorrhoeae:research advances

头孢曲松作为淋病一线治疗药物之一,目前仍比较敏感,国内外尚未报道临床治疗失败病例,体外药敏试验也只发现少数散发头孢曲松耐药株。但是,淋病奈瑟球菌(淋球菌)对头孢曲松敏感性下降的趋势已很明显,而且中国少数地区淋球菌头孢曲松耐药株检出率>5%,故应密切监测淋球菌对头孢曲松的敏感性变化。目前淋球菌对头孢曲松的耐药机制尚不明确,penA和m trR等基因突变在耐药中的作用成为关注热点。

Ceftriaxone is a first-line drug for Neisseria gonorrhoeae treatment. In vitro antimicrobial susceptibility studies have found few N. gonorrhoeae strains resistant to ceftriaxone, though clinical ceftriaxone treatment failure has not been reported worldwide. Furthermore, ceftriaxone resistance rates are a- bove 5% in few areas of China. In view of the tendency of N. gonorrhoeae less susceptible to ceftriaxone, it is necessary to monitor ceftriaxone resistance to N. gonorrhoeae. Nowadays the mechanism of ceftriaxone resistance has not been fully elucidated, most studies focus on mutations in the penA and mtrR genes.